Press Releases JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Market Closed - Japan Exchange Other stock markets 11:30:00 09/05/2024 am IST			5-day change	1st Jan Change
799 ^JPY	-0.12%		-0.87%	-31.83%

25/04	JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024	CI
21/03	US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	20/03	AQ
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion	19/03	BU
JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community	29/02	BU
JCR Pharmaceuticals Research Presentations at WORLDSymposium 2024 Showcase JR-141 and Other Investigational Treatments for Lysosomal Storage Disorders	15/02	AQ
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders	14/02	BU
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024	25/01	BU
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration	21/12	BU
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology	21/12	BU
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)	15/12	BU
Mucopolysaccharidosis Type I Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	16/11	AQ
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	10/11	BU
JCR Pharmaceuticals : FY2023 First-Half Results Briefing Session -Material-（2,157KB）	02/11	PU
PHC IVD and JCR Announce Upgrade of Melon Nikki, Medication Management App for Pediatric Patients Undergoing Growth Hormone Therapy	02/23/02	AQ
JCR Pharmaceuticals Announces 52-week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I	02/23/02	AQ
JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)	29/23/29	BU
PHC and JCR Pharmaceuticals Jointly Develop and Launch Sales of Electric Injector 'Growject Duo' Exclusively for Human Growth Hormone Preparation 'Growject'	30/23/30	AQ
JCR Pharmaceuticals : FY2023-Q1 Financial Report (Apr. 1-Jun. 30, 2023)（413KB）	21/23/21	PU
JCR Pharmaceuticals : FY2022 Second-Half Results Briefing Session -Financial Results -（962KB）	08/23/08	PU
JCR Pharmaceuticals : FY2022 Full Year Financial Report（475KB）	30/23/30	PU
JCR Pharmaceuticals : FY2022 Second-Half Results Briefing Session -Script-（6,169KB）	16/23/16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Press Releases

Filters